CW July 2004
Volume 13Issue Number 7 July 2004 ISSN 10593802 Phase I Clinical Trial Results of an Investigational Drug for Advanced Prostate CancerThe investigational compound J591 is a monoclonal antibody that targets a specific molecule on prostate cancer cells and can carry a radionuclide. When attached to the radionuclide, this radiolabeled antibody is found to have antitumor activity.
Go to Previous Page Go to Next Page Source & Additional Reading N. Bander et al., Journal of Clinical Oncology, July 1, 2004. Purchase Downloadable Full-text PDF of Article: $10.00 Subscription is more cost effective than purchasing PDFs on-the-fly. Click here for details. Download Complete Issue CW July 2004Purchase Downloadable Full-text PDF of Complete Issue: $20.00 |
|
Member Login | Home | Offices | Subscribe | Glossary | Cancer Technologies | Contact Us
Adenine Press, 2066 Central Avenue, Schenectady, NY 12304 USA |
Re-initialize IP-based Login |
